Replace months of manual commercial, regulatory, IP, clinical, and formulation analysis with structured, evidence-backed opportunities your team can act on immediately.
Ready to deploy for US FDA · EU EMA · UK MHRA. On-premises & private-cloud deployment
Built specifically for your context, using private data and customized workflows, orchestrated agents move every opportunity through the cycle with the right precedent, evidence, alternatives, and traceability to accelerate portfolio decisions.
Agents propose, your experts decide. We call this co-intelligence.
Built for regulated pharma. Your proprietary pipeline data never has to leave your walls. Deployment, residency, and access stay under your control.
Full control over data residency and access within your own infrastructure. No forced multi-tenant cloud.
Internal pipeline data, historical assessments, and institutional records integrated with complete data isolation.
Tailor scoring models, evaluation criteria, and workflows to fit how your team already works.
Every opportunity links back to its source. Outputs are reviewable, versioned, and built to satisfy internal governance.
In rethink's engagement with Revio, a single scan surfaced 300+ scored opportunities and 30+ development-ready strategies. That's a full cross-functional screening cycle compressed from months into days, with every output traceable to source.
Early-stage by design: we partner closely with a small number of teams and build the platform around real portfolio decisions. Founding team backgrounds span regulatory strategy, formulation science, and applied AI.
From first screen to IND-ready strategy, rethink works alongside the experts making the portfolio call.
Turn existing assets into new lifecycle and brand-extension opportunities.
Build a sharper, evidence-backed pipeline faster than headcount allows.
Diligence target assets at a depth and speed manual processes can't reach.
Surface opportunities where your technology creates a defensible edge.
Decades inside pharma R&D, regulatory strategy, formulation science, and applied AI, with the NDAs, INDs, and marketed products to show for it.
Scientist-entrepreneur with 25+ years in global life-sciences R&D and business. Contributed to 15 NDAs, 25+ INDs, and numerous pre-INDs, 505(b)(2), hybrid, and ANDA programs, launching products across oncology, neurology, pain, inflammation, rare diseases, and infection. Holds dual master's degrees in chemistry and pharmacokinetics.
Previously PPD · Vertex · Glenmark · Sapien · Rhizen · Dr. Reddy's–Aurigene
Nearly 20 years in pharma product development and a serial entrepreneur. Has developed 20+ products for regulated markets, including first-to-file generics and 505(b)(2) programs, pairing deep biological domain knowledge with hands-on process design, scale-up, and commercialization. Founder of Novick Biosciences, a CDMO in India.
Previously Sanofi · GSK · Quintiles
20+ years across investing, equity research, portfolio management, and startup building. Pairs financial rigor with strong product intuition to guide growth, pricing, and long-term value creation, and bridges data, technology, and market strategy to build scalable, domain-specific AI. CFA Level II with an MBA in finance.
Previously Centrum · Avendus Spark Capital · iLabs
20+ years in preclinical drug discovery, leading the preclinical characterization of five clinical candidates and steering cross-functional teams from early research through development-candidate selection. 30+ publications, 19 co-authored patents, and postdoctoral training at UMass Medical School and the NIH.
Previously Glenmark · Insilico Medicine · Enveda
20+ years in product ideation and formulation development across parenteral, oral, and ophthalmic dosage forms for global markets. Contributed to 50+ generic and 505(b)(2) programs, including NCE-1, with multiple scientific-advice, pre-IND, and IND filings. 25+ publications, 10+ patents, and a PhD in pharmaceutical sciences.
Previously Tiefenbacher · Leiutis · Hetero
IIM MBA with 7+ years in strategic finance and value creation. Builds enterprise forecasting and performance governance, investment-grade business cases, and group-level financial planning, including an IFRS-compliant five-year P&L for a billion-dollar business across five operating units.
Previously Cognizant · Aurore · Extrovis
Architects the end-to-end ReThink platform, fusing agentic AI workflows with pharma-grade controls for data, model lifecycle, orchestration, security, and governance. Builds large-scale data platforms with governed analytics and ML-ready feature stores. 2× founder.
Previously CERN · Reliance Jio · Vume Interactive · GSoC
Design leader with 25+ years driving business value through user psychology, product strategy, and interface innovation. Has designed and scaled platforms for tens of millions of users across gaming, BFSI, startups, and the creator economy, building design teams and scalable design systems.
Previously Ness · Innova · Innopark · A23
Send us the molecule or the question. We'll take it from first screen to development-ready strategy, scored against your criteria.
Share a molecule, opportunity, or pathway and the founding team will schedule a demo.